Laparoscopic Adjustable Gastric Banding for Morbidly Obese Adolescents Affects Android Fat Loss, Resolution of Comorbidities, and Improved Metabolic Status
Abstract presented at the American College of Surgeons 93rd Clinical Congress, Surgical Forum, New Orleans, LA, October 2007, and the Section on Surgery, 59th Annual Meeting of the American Academy of Pediatrics, San Francisco, CA, October 2007.
Received 12 June 2009; received in revised form 24 July 2009; accepted 24 July 2009. published online 31 August 2009.
Background
The distribution of weight loss and its impact on metabolic health has not been documented for laparoscopic adjustable gastric banding (LAGB) in the adolescent population. We hypothesized that LAGB in obese adolescents would result in loss of android fat mass, resolution of comorbidities, and improvement in metabolic status.
Study Design
Adolescents ages 14 to 17 who met criteria for bariatric surgery were enrolled in our FDA-approved LAGB trial. Demographic data, body mass index, body composition and bone density, laboratory evaluations, and comorbid conditions were assessed pre- and postoperatively.
Results
Forty-five patients had complete 1-year followup and 41 patients had complete 2-year followup. Mean preoperative weight was 299 ± 57 lb and body mass index was 48 ± 6.4 kg/m2. The percent excess weight losses at 6 months, 1 year, and 2 years were 31 ± 16, 46 ± 21, and 47 ± 22, respectively. At 1-year followup, patients after LAGB had a significant decrease in their total and android fat mass. In addition, 47 of 85 identified comorbidities (55%) were completely resolved and 25 (29%) were improved in comparison with baseline. Improvements in alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, hemoglobin A1c, fasting insulin, triglycerides, and high density lipoprotein, were also seen.
Conclusions
The percent excess weight loss after LAGB in morbidly obese adolescents is approximately 45% at 1- and 2-year followup, with the majority of weight loss consisting of android fat mass. Resolution or improvement of comorbidities is seen, and improved metabolic status, as demonstrated by liver function tests, lipid levels, and measures of glucose homeostasis, may be expected. These data support LAGB as an appropriate surgical option for morbidly obese adolescents.
aDivision of Pediatric Surgery, New York University School of Medicine, New York, NY
bDepartment of Surgery, New York University School of Medicine, New York, NY
cDepartment of Medicine, New York University School of Medicine, New York, NY
Correspondence address: Evan P Nadler, MD, New York University School of Medicine, 530 First Ave, Suite 10W, New York, NY 10016
Disclosure Information: Drs Nadler, Ren, and Fielding are investigators for Allergan, which makes the device used in this study and Drs Ren and Fielding are also on Allergan's speaker's bureau.
Funded by the Harris Obesity Prevention Effort (HOPE) at NYU.
ABSTRACT